KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Other Operating Expenses: 2016-2025

Historic Other Operating Expenses for Sarepta Therapeutics (SRPT) over the last 8 years, with Jun 2025 value amounting to $707.2 million.

  • Sarepta Therapeutics' Other Operating Expenses rose 1466.52% to $707.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $977.6 million, marking a year-over-year increase of 447.01%. This contributed to the annual value of $321.5 million for FY2024, which is 215.20% up from last year.
  • Sarepta Therapeutics' Other Operating Expenses amounted to $707.2 million in Q2 2025, which was up 432.13% from $132.9 million recorded in Q4 2024.
  • Sarepta Therapeutics' 5-year Other Operating Expenses high stood at $707.2 million for Q2 2025, and its period low was $19.7 million during Q2 2021.
  • For the 3-year period, Sarepta Therapeutics' Other Operating Expenses averaged around $131.2 million, with its median value being $45.1 million (2024).
  • Its Other Operating Expenses has fluctuated over the past 5 years, first crashed by 69.91% in 2021, then spiked by 1,466.52% in 2025.
  • Sarepta Therapeutics' Other Operating Expenses (Quarterly) stood at $31.9 million in 2021, then decreased by 2.96% to $31.0 million in 2022, then soared by 45.07% to $44.9 million in 2023, then surged by 195.75% to $132.9 million in 2024, then skyrocketed by 1,466.52% to $707.2 million in 2025.
  • Its Other Operating Expenses was $707.2 million in Q2 2025, compared to $132.9 million in Q4 2024 and $92.3 million in Q3 2024.